26096-30-0

Basic information

• Product Name: (1-benzylazetidine-3,3-diyl)dimethanol
• Synonyms: (1-benzylazetidine-3,3-diyl)dimethanol;N-benzyl-3,3-bis(hydroxymethyl)azetidine
• CAS NO: 26096-30-0
• Molecular Formula: C₁₂H₁₇NO₂
• Molecular Weight: 207.26888
• Mol File: 26096-30-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1-benzylazetidine-3,3-diyl)dimethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1-benzylazetidine-3,3-diyl)dimethanol(26096-30-0)
• EPA Substance Registry System: (1-benzylazetidine-3,3-diyl)dimethanol(26096-30-0)

Safety Data

• Hazardous Substances Data: 26096-30-0(Hazardous Substances Data)

Usage

General Description

(1-benzylazetidine-3,3-diyl)dimethanol is a chemical compound that belongs to the family of azetidines, which are four-membered heterocycles containing one nitrogen atom. It is a diol, meaning it has two hydroxyl groups, and it also contains a benzyl group. (1-benzylazetidine-3,3-diyl)dimethanol can be used in organic synthesis as a building block for the preparation of various molecules, especially in the field of pharmaceuticals and agrochemicals. Its unique structure and reactivity make (1-benzylazetidine-3,3-diyl)dimethanol a versatile and valuable intermediate in the production of complex organic compounds.

Upstream product

• 106014-95-3 N-benzyl-3-hydroxymethyl-azetidine-3-carboxylic acid 
• 100-46-9 benzylamine 
• 20605-01-0 diethyl bis(hydroxymethyl)malonate 
• 642411-11-8 3,3‐diethyl 1‐benzylazetidine‐3,3‐dicarboxylate 
• 137266-85-4 1-benzyl-3-chloromethylazetidine-3-carboxylic acid ethyl ester 
• 43153-20-4 5,5-bis-bromomethyl-2,2-dimethyl-[1,3]dioxane 

Downstream Products

• 1041026-64-5 2-benzyl-6-(p-toluenesulfonyl)-2,6-diazaspiro[3.3]heptane 
• 1041026-67-8 tert-butyl 6-(p-toluenesulfonyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate 
• 1041026-71-4 2,6-diazaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester hemioxylate 
• 1016233-34-3 1-[(7-benzyloxymethyl-4-tert-butoxy-9-deazapurin-9-yl)methyl]azetidine-3,3-dimethanol 
• 1016232-92-0 azetidine-3,3-dimethanol hydrochloride 
• 1016233-08-1 3,3-bis(hydroxymethyl)azetidine-1-carboxylic acid tert-butyl ester 
• 36476-78-5 3-azetidinecarboxylic acid 
• 106014-87-3 1-(phenylmethyl)-3,3-azetidinedicarboxylic acid 

Relevant articles and documents

1-azaspirocycle compound, and preparation method and applications thereof

The invention discloses a 1-azaspirocycle compound, and preparation method and applications thereof, and belongs to the field of pharmaceutical chemistry. The 1-azaspirocycle compound with a structurerepresented by formula I, or a pharmaceutically acceptable salt or a stereisomer or a solvate or a prodrug thereof is capable of realzing combination with Autotaxin, can be taken as an Autotaxin inhibitor, and can be used for prevention and treatment of diseases with Autotaxin expression increasing pathological characteristics such as cancer and fibrosis diseases especially pulmonary fibrosis andhepatic fibrosis, metabolic diseases, myelodysplastic syndrome, cardiovascular diseases, autoimmune diseases, inflammation, neurological diseasses, or pain. Compared with single component inhibitors,the 1-azaspirocycle compound and the derivatives possesses following advantages: blocking and interfacing at the upsteam of a plurality of key signal channels are realized, tumor cell growth and transfer are relieved or dalyed, early caused drug resistance is avoided, and novel means are provided for treatment of tumor cells.

FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.

AZETIDINE ANALOGUES OF NUCLEOSIDASE AND PHOSPHORYLASE INHIBITORS

Azetidine analogues of nucleosidase and nucleoside phosphorylase inhibitors having the general formula (I), the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, methods of treating certain diseases using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds wherein W and X are each independently selected from hydrogen, CH2OH, CH2OQ and CH2SQ; Y and Z are each independently selected from hydrogen, halogen, CH2OH, CH2OQ, CH2SQ, SQ, OQ and Q; Q is an alkyl, aralkyl or aryl group each of which may be optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy; R1 is a radical of the formula (II) or R1 is a radical of the formula (III) A is selected from N, CH and CR2, where R2 is selected from halogen, alkyl, aralkyl, aryl, OH, NH2, NHR3, NR3R4 and SR5, where R3, R4 and R5 are each alkyl, aralkyl or aryl groups optionally substituted with hydroxy or halogen, and where R2 is optionally substituted with hydroxy or halogen when R2 is alkyl, aralkyl or aryl; B is selected from hydroxy, NH2, NHR6, SH, hydrogen and halogen, where R6 is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; D is selected from hydroxy, NH2, NHR7, hydrogen, halogen and SCH3, where R7 is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; E is selected from N and CH; G is a C1-4 saturated or unsaturated alkyl group optionally substituted with hydroxy or halogen, or G is absent; or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.